Clinical trial
A Phase 1a/1b, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABX1100 in Normal Healthy Volunteers and Late-onset Pompe Disease Patients
NCT06109948 is registered in ClinicalTrials.gov with Aro Biotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABX1100 in Normal Healthy Volunteers and Late-onset Pompe Disease Patients
- Lead sponsor
- Aro Biotherapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 19, 2023
- Completion date
- February 13, 2026
- Enrollment
- 46 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
healthy, late onset pompe disease